课题基金 / 基金详情

Therapeutic targeting of immune-inflammation pathway via IL23-IL17 axis in Endometriosis

Therapeutic targeting of immune-inflammation pathway via IL23-IL17 axis in Endometriosis
通过 IL23-IL17 轴靶向免疫炎症途径治疗子宫内膜异位症
批准号：
356264
负责人：
Tayade Chandrakant
金额：
$45.14万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=356264&lang=en
关键词：
Cytokines/Chemokines Diagnostic Markers Endometriosis Immune Dysfunction Infertility Inflamamtion Therapeutic Target

项目摘要

项目成果

Tayade Chandrakant的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Endometriosis, characterized by growth of endometrial lining outside of the uterus, is the most prevalent global cause for hysterectomy, infertility and pelvic pain. It affects 6-10% of reproductive age women and 35-50% in women with pelvic pain/unexplain
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unique extracellular vesicle signatures in the pathophysiology of endometriosis
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting
Role of IL-33-innate lymphoid cells 2 (ILC2) pathway in endometriosis pathophysiology and therapeutic targeting.
Investigating the role of endocannabinoids in endometriosis pathophysiology and determine efficacy of cannabinoids as a novel therapeutic modality.
海外基金